EGFR and lung cancer: Recent work also shows that AMPK activation sensitizes EGFR wild type H1299 cells and tumors to erlotinib treatment, suggesting a role of AMPK activation in modulating EGFR signaling and drug sensitivity in lung cancer cells [31].